Japan's Canon Aims to Buy Optopol Technology Of Poland For $45 Million
This article was originally published in PharmAsia News
Canon of Japan has begun the process of acquiring Optopol Technology of Poland, offering $45 million to shareholders for all shares
You may also be interested in...
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
A top executive at the Swedish company spoke with Medtech Insight about how the mobility and data reliability of 5G cellular technology will change how medtech manufacturers design their products.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.